创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction to IC50 Characterization

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-27 15:11
  • Views:

(Summary description)Introduction: In the field of drug discovery and development, IC50 value is an important parameter to measure the affinity between a drug and its target. As a company dedicated to innovative drug discovery and development, the IC50 characteristics of InnoModels Biotechnology have attracted much attention. In this paper, we will briefly introduce the IC50 characteristics of InnoModels Biotechnology

InnoModels: Introduction to IC50 Characterization

(Summary description)Introduction: In the field of drug discovery and development, IC50 value is an important parameter to measure the affinity between a drug and its target. As a company dedicated to innovative drug discovery and development, the IC50 characteristics of InnoModels Biotechnology have attracted much attention. In this paper, we will briefly introduce the IC50 characteristics of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-27 15:11
  • Views:
Information

Introduction: In the field of drug discovery and development, IC50 value is an important parameter to measure the affinity between a drug and its target. As a company dedicated to innovative drug discovery and development, the IC50 characteristics of InnoModels Biotechnology have attracted much attention. In this paper, we will briefly introduce the IC50 characteristics of InnoModels Biotechnology.
Meaning of IC50 value
IC50 value, i.e. half inhibitory concentration, is the concentration of drug required to inhibit half of the maximum effect. It is an important indicator for assessing the affinity between a drug and its target. The lower the IC50 value, the closer the drug binds to the target and the more potent the drug is. In the process of drug development, the determination of IC50 value is of great significance for screening drug candidates, evaluating the mechanism of drug action and optimizing drug structure.
Features of InnoModels Biotechnology IC50
1. Rich experience in drug discovery and development
InnoModels Biotechnology has an experienced R&D team with profound knowledge in drug screening, optimization and mechanism of action research. This enables the company to have high accuracy and reliability in the determination of IC50 value.
2. Advanced experimental technology
The company adopts advanced experimental technologies, such as high content imaging system and bioinformatics analysis, to precisely analyze the interaction between drugs and targets. This helps to improve the accuracy and sensitivity of IC50 value determination.

 


3. Extensive Collaboration Network
InnoModels Biotechnology has established an extensive cooperation network and maintains close cooperation with many research institutes, medical organizations and enterprises at home and abroad. This provides the company with abundant resources and channels for IC50 value research, and promotes technological innovation and industrial development.
4. Continuous innovation ability
The Company is committed to the research and development of new drugs and continuously invests funds and human resources to promote scientific research and innovation. This has enabled the company to maintain a leading position in IC50 value research, providing strong support for drug development.
5. Strict quality control
Focusing on product quality, InnoModels Biotechnology has established a strict quality control system to ensure the accuracy and reliability of IC50 value measurement results. This has earned the company a good reputation and won the trust of customers.
Conclusion
As a biotechnology company with strong IC50 value determination capability, InnoModels Biotechnology has high competitiveness in the field of drug research and development. In the future, the company will continue to utilize its own advantages to promote the research and development of innovative drugs and contribute to the cause of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司